Genome-wide association study of antidepressant treatment-emergent suicidal ideation

Neuropsychopharmacology

Volumn 37, Issue 3, 2012, Pages 797-807

  Menke, Andreas ^a   Domschke, Katharina ^b   Czamara, Darina ^a   Klengel, Torsten ^a   Hennings, Johannes ^a   Lucae, Susanne ^a   Baune, Bernhard T ^c   Arolt, Volker ^b   Müller Myhsok, Bertram ^a   Holsboer, Florian ^a   Binder, Elisabeth B ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

antidepressants; genetic markers; major depression; suicidal ideation; suicide; TESI

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE; MIRTAZAPINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ALLELE; ARTICLE; DEPRESSION; DRUG EFFECT; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SUICIDAL IDEATION;

ADOLESCENT; ADULT; AGED; ALLELES; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SUICIDAL IDEATION;

EID: 84855865563     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.257     Document Type: Article

References (71)

1. Angst J, Angst F, Gerber-Werder R, Gamma A (2005). Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years" follow-up. Arch Suicide Res 9:279-300. (Pubitemid 40977549)
2. Bostwick JM, Pankratz VS (2000). Affective disorders and suicide risk: a reexamination. Am J Psychiatry 157:1925-1932.
3. Brent D, Melhem N, Ferrell R, Emslie G, Wagner KD, Ryan N et al (2010a). Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry 167:190-197.
4. Brent D, Melhem N, Turecki G (2010b). Pharmacogenomics of suicidal events. Pharmacogenomics 11:793-807.
5. Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L et al (2009). Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry 166:418-426.
6. Brent DA, Mann JJ (2005). Family genetic studies, suicide, and suicidal behavior. Am J Med Genet C 133:13-24. (Pubitemid 40194125)
7. Carpenter DJ, Fong R, Kraus JE, Davies JT, Moore C, Thase ME (2011). Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. J Clin Psychiatry (in press).
8. Carter CJ (2009). Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: cytomegalovirus, influenza, herpes simplex, rubella, and Toxoplasma gondii. Schizophr Bull 35:1163-1182.
9. Cassidy F, Zhao C, Badger J, Claffey E, Dobrin S, Roche S et al (2007). Genome-wide scan of bipolar disorder and investigation of population stratification effects on linkage: support for susceptibility loci at 4q21, 7q36, 9p21, 12q24, 14q24, and 16p13. Am J Med Genet B 144 B: 791-801. (Pubitemid 47417209)
10. Derogatis LR (1983). Misuse of the symptom checklist 90. Arch Gen Psychiatry 40:1152-1153.
11. Devlin B, Roeder K, Wasserman L (2001). Genomic control, a new approach to genetic-based association studies. Theor Popul Biol 60:155-166. (Pubitemid 34235086)
12. Domschke K, Dannlowski U, Ohrmann P, Lawford B, Bauer J, Kugel H et al (2008). Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 18:751-759.
13. Dudbridge F, Gusnanto A (2008). Estimation of significance thresholds for genomewide association scans. Genet Epidemiol 32:227-234. (Pubitemid 351550369)
14. Elashoff M, Higgs BW, Yolken RH, Knable MB, Weis S, Webster MJ et al (2007). Meta-analysis of 12 genomic studies in bipolar disorder. J Mol Neurosci 31:221-243. (Pubitemid 47338416)
15. Gibbons RD (2007). Dr. Gibbons Replies. Am J Psychiatry 164:1908-1910. (Pubitemid 351739248)
16. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA et al (2007). Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 164:1356-1363. (Pubitemid 47461135)
17. Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P (2003). Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ 326:1008.
18. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
19. Hamilton M (1967). Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
20. Hammad TA, Laughren T, Racoosin J (2006). Suicidality in Pediatric Patients Treated With Antidepressant Drugs. Arch Gen Psychiatry 63:332-339. (Pubitemid 43345358)
21. Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S et al (2009). Clinical characteristics and treatment outcome in a representative sample of depressed inpatientsfindings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 43:215-229.
22. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S et al (2009). A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 66:966-975.
23. Jick H, Kaye JA, Jick SS (2004). Antidepressants and the risk of suicidal behaviors. Jama 292:338-343. (Pubitemid 38944257)
24. Jureidini J (2007). The Black Box Warning: decreased prescriptions and increased youth suicide? Am J Psychiatry 164:1907. (Pubitemid 351739245)
25. Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA (2006). The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 163:813-821. (Pubitemid 44464528)
26. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602. (Pubitemid 40973434)
27. Laje G, Allen AS, Akula N, Manji H, John Rush A, McMahon FJ (2009). Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet Genomics 19:666-674.
28. Laje G, Paddock S, Manji H, Rush AJ, Wilson AF, Charney D et al (2007). Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 164:1530-1538. (Pubitemid 350069732)
29. Leon AC (2007). The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. Am J Psychiatry 164:1786-1789. (Pubitemid 351739229)
30. Libby AM, Brent DA, Morrato EH, Orton HD, Allen R, Valuck RJ (2007). Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 164:884-891. (Pubitemid 46972903)
31. Libby AM, Orton HD, Valuck RJ (2009). Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 66:633-639.
32. Licinio J, Wong ML (2005). Depression, antidepressants and suicidality: a critical appraisal. Nat Rev Drug Discov 4:165-171. (Pubitemid 40277496)
33. Mann JJ (2005). The medical management of depression. N Engl J Med 353:1819-1834.
34. March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J et al (2007). The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 64:1132-1143.
35. Marshall E (2004). Antidepressants and children: buried data can be hazardous to a company's health. Science 304:1576-1577. (Pubitemid 38765818)
36. Masand P, Gupta S, Dewan M (1991). Suicidal ideation related to fluoxetine treatment. N Engl J Med 324:420.
37. Menke A, Lucae S, Kloiber S, Horstmann S, Bettecken T, Uhr M et al (2008). Genetic markers within glutamate receptors associated with antidepressant treatment-emergent suicidal ideation. Am J Psychiatry 165:917-918. (Pubitemid 351948730)
38. Morgan OW, Griffiths C, Majeed A (2004). Association between mortality from suicide in England and antidepressant prescribing: an ecological study. BMC Public Health 4:63.
39. Morrato EH, Libby AM, Orton HD, Degruy III FV, Brent DA, Allen R et al (2008). Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 165:42-50. (Pubitemid 351704551)
40. Mulder RT, Joyce PR, Frampton CM, Luty SE (2008). Antidepressant treatment is associated with a reduction in suicidal ideation and suicide attempts. Acta Psychiatr Scand 118:116-122. (Pubitemid 351962156)
41. Nakagawa A, Grunebaum MF, Ellis SP, Oquendo MA, Kashima H, Gibbons RD et al (2007). Association of suicide and antidepressant prescription rates in Japan, 1999-2003. J Clin Psychiatry 68:908-916. (Pubitemid 47015491)
42. Olfson M, Marcus SC, Druss BG (2008). Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 65:94-101.
43. Olfson M, Shaffer D (2007). SSRI prescriptions and the rate of suicide. Am J Psychiatry 164:1907-1908. (Pubitemid 351739246)
44. Pato CN, Pato MT, Kirby A, Petryshen TL, Medeiros H, Carvalho C et al (2004). Genome-wide scan in Portuguese Island families implicates multiple loci in bipolar disorder: fine mapping adds support on chromosomes 6 and 11. Am J Med Genet B 127 B: 30-34. (Pubitemid 38542309)
45. Perlis RH, Beasley Jr CM, Wines Jr JD, Tamura RN, Cusin C, Shear D et al (2007a). Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom 76:40-46. (Pubitemid 46005718)
46. *D study. Arch Gen Psychiatry 64:689-697. (Pubitemid 46878669)
47. Perroud N (2011). Suicidal ideation during antidepressant treatment: do genetic predictors exist? CNS Drugs 25:459-471.
48. Perroud N, Aitchison KJ, Uher R, Smith R, Huezo-Diaz P, Marusic A et al (2009). Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology 34:2517-2528.
49. Perroud N, Bondolfi G, Uher R, Gex-Fabry M, Aubry JM, Bertschy G et al (2011). Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 12:365-377.
50. Perroud N, Uher R, Ng MY, Guipponi M, Hauser J, Henigsberg N et al (2010). Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics J (in press).
51. Posner K, Oquendo MA, Gould M, Stanley B, Davies M (2007). Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164:1035-1043. (Pubitemid 47121392)
52. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006). Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38:904-909. (Pubitemid 44141658)
53. Rihmer Z, Akiskal H (2006). Do antidepressants t (h) reat (en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord 94:3-13. (Pubitemid 44093033)
54. Rucci P, Frank E, Scocco P, Calugi S, Miniati M, Fagiolini A et al (2011). Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial. Depress Anxiety 28:303-309.
55. Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC et al (2006). An evaluation of the quick inventory of depressive symptomatology and the Hamilton Rating Scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 59:493-501. (Pubitemid 43320536)
56. Rush AJ, Trivedi MH, Carmody TJ, Ibrahim HM, Markowitz JC, Keitner GI et al (2005). Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. Neuropsychopharmacology 30:405-416. (Pubitemid 40129492)
57. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN et al (2003). The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and selfreport (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54:573-583. (Pubitemid 37289444)
58. Seemuller F, Riedel M, Obermeier M, Bauer M, Adli M, Mundt C et al (2009). The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. Int J Neuropsychopharmacol 12:181-189.
59. Statham DJ, Heath AC, Madden PA, Bucholz KK, Bierut L, Dinwiddie SH et al (1998). Suicidal behaviour: an epidemiological and genetic study. Psychol Med 28:839-855. (Pubitemid 28393563)
60. Stopkova P, Saito T, Papolos DF, Vevera J, Paclt I, Zukov I et al (2004). Identification of PIK3C3 promoter variant associated with bipolar disorder and schizophrenia. Biol Psychiatry 55:981-988. (Pubitemid 38581913)
61. Szanto K, Mulsant BH, Houck PR, Dew MA, Dombrovski A, Pollock BG et al (2007). Emergence, persistence, and resolution of suicidal ideation during treatment of depression in old age. J Affect Disord 98:153-161. (Pubitemid 46055277)
62. Tang K, Fu DJ, Julien D, Braun A, Cantor CR, Koster H (1999). Chip-based genotyping by mass spectrometry. Proc Natl Acad Sci USA 96:10016-10020. (Pubitemid 29422504)
63. Tang R, Zhao X, Fang C, Tang W, Huang K, Wang L et al (2008). Investigation of variants in the promoter region of PIK3C3 in schizophrenia. Neurosci Lett 437:42-44.
64. Teicher MH, Glod C, Cole JO (1990). Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147:207-210. (Pubitemid 20060476)
65. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T et al (2004). The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 34:73-82. (Pubitemid 38139442)
66. Valuck RJ, Libby AM, Orton HD, Morrato EH, Allen R, Baldessarini RJ (2007). Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 164:1198-1205. (Pubitemid 47292408)
67. Wang L, Budolfson K, Wang F (2011). Pik3c3 deletion in pyramidal neurons results in loss of synapses, extensive gliosis and progressive neurodegeneration. Neuroscience 172:427-442.
68. Westfall PH (1993). Resampling-based Multiple Testing. Wiley: New York.
69. Wigginton JE, Cutler DJ, Abecasis GR (2005). A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 76:887-893. (Pubitemid 40563110)
70. Wirshing WC, Van Putten T, Rosenberg J, Marder S, Ames D, Hicks-Gray T (1992). Fluoxetine, akathisia, and suicidality: is there a causal connection? Arch Gen Psychiatry 49:580-581.
71. Zisook S, Trivedi MH, Warden D, Lebowitz B, Thase ME, Stewart JW et al (2009). Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STARD study. J Affect Disord 117:63-73.